Treatment of idiopathic Parkinson's disease with traditional chinese herbal medicine: a randomized placebo-controlled pilot clinical study.
The objective of this clinical study is to examine the effects of a Chinese herbal medicine formula (Jia Wei Liu Jun Zi Tang: JWLJZT) on motor and non-motor symptoms, and on complications of conventional therapy in idiopathic Parkinson's disease (PD), using an add-on design. Fifty-five patients with PD were randomly allocated to receive either Chinese herbal medicine or placebo for 24 weeks. Primary outcome measure was the 39-item Parkinson's Disease Questionnaire (PDQ-39). Secondary outcome measures included the Unified Parkinson's Disease Rating Scale (UPDRS), Short-Form-36 Health Survey (SF-36), Geriatric Depression Scale (GDS), home diaries, and a range of category rating scales. JWLJZT resulted in a significant improvement in the UPDRS IVC when compared with placebo at 12 weeks (P = .039) and 24 weeks (P = .034). In addition, patients in the Chinese herbal medicine group also showed significant improvement in PDQ-39 communication scores at 12 weeks (P = .024) and 24 weeks (P = .047) when compared with the placebo group. There were no significant differences between treatment and control groups for SF-36 variables, GDS score or the mean daily "on-off" time. One case of mild diarrhea was noted in the treatment group. The findings suggest that JWLJZT can relieve some non-motor complications of conventional therapy and improve the communication ability in patients with PD. The results of this pilot study warrant larger multi-center clinical studies to assess long-term efficacy and tolerability of JWLJZT, and to elucidate the mechanisms by which it affects PD function.
Kum
Wan Fung
WF
School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong.
Durairajan
Siva Sundara Kumar
SS
Bian
Zhao Xiang
ZX
Man
Sui Cheung
SC
Lam
Yuen Chi
YC
Xie
Li Xia
LX
Lu
Jia Hong
JH
Wang
Yan
Y
Huang
Xian Zhang
XZ
Li
Min
M
J Clin Epidemiol. 1998 Nov;51(11):1139-47
9817131
Age Ageing. 2006 May;35(3):235-9
16540492
N Engl J Med. 2003 Apr 3;348(14):1356-64
12672864
Acta Neurol Scand. 2004 Mar;109(3):228-31
14763963
Mov Disord. 2006 Oct;21(10):1709-15
16830309
Acta Neurol Scand. 2005 Jan;111(1):21-8
15595934
Folia Phoniatr Logop. 1994;46(1):9-17
8162135
Clin Neuropharmacol. 1997 Dec;20(6):523-30
9403226
Eur Neurol. 1973;10(5):301-10
4789106
Behav Pharmacol. 2006 Sep;17(5-6):403-10
16940761
Neurology. 2000;55(12 Suppl 6):S2-6
11188970
Singapore Med J. 1994 Oct;35(5):477-80
7701365
Neurology. 2001 Sep 11;57(5):790-4
11552005
Behav Neurol. 1999 Jan 1;11(3):131-7
22387592
Psychiatry Clin Neurosci. 2000 Oct;54(5):579-82
11043809
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
1564476
J Speech Hear Disord. 1978 Feb;43(1):47-57
633872
J Clin Epidemiol. 2004 Jan;57(1):40-4
15019009
Zhong Xi Yi Jie He Xue Bao. 2006 May;4(3):233-42
16696907
Mov Disord. 2001 May;16(3):448-58
11391738
Mov Disord. 2002 Sep;17(5):1036-40
12360555